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Available online 20 December 2016Aims: Chronic heart failure (HF) is associated with activation of blood coagulation but there is a lack of
prospective studies on the association between coagulation markers and incident HF in general populations.
We have examined the association between the coagulation markers ﬁbrinogen, von Willebrand Factor
(VWF), Factors VII, VIII and IX, D-dimer, activated protein C (APC) and activated partial thromboplastin time
(aPPT) with NT-proBNP and incident HF.
Methods and results: Prospective study of 3366 men aged 60–79 years with no prevalent HF, myocardial
infarction or venous thrombosis and who were not on warfarin, followed up for a mean period of 13 years, in
whom there were 203 incident HF cases. D-dimer and vWF were signiﬁcantly and positively associated with
NT-proBNP (a marker of neurohormonal activation and left ventricular wall stress) even after adjustment for
age, lifestyle characteristics, renal dysfunction, atrial ﬁbrillation (AF) and inﬂammation (C-reactive protein).
By contrast Factor VII related inversely to AF and NT-proBNP even after adjustment. No association was seen
however between the coagulation markers VWF, Factor VII, Factor VIII, Factor IX, D-dimer, APC resistance or
aPPT with incident HF in age-adjusted analyses. Fibrinogen was associated with incident HF but this was
abolished after adjustment for HF risk factors.
Conclusion: Coagulation activity is not associated with the development of HF. However D-dimer and
vWF were signiﬁcantly associated with NT-proBNP, suggesting that increased coagulation activity is
related to cardiac stress; and the increased coagulation seen in HF patients may in part be a consequence
of neurohormonal activation.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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D-dimer
NT-proBNP
Heart failure1. Introduction
It is well established that patients with chronic heart failure (HF)
have systemic activation of blood coagulation, which may partly reﬂect
systemic activation of inﬂammation, and which may increase their risk
of arterial and venous thromboembolic events and with adverse prog-
nosis [1–4]. Such patients have increased levels of ﬁbrinogen and the
Factor VIII – vonWillebrand factor (VWF) complex; and elevated levels
of coagulation activation markers including ﬁbrin D-dimer [1–4].
Plasma levels of ﬁbrinogen and VWF are associated with adverse
prognosis in such patients [5]. Moreover ﬁbrinogen and vWF-VIII have
been associated with incident atrial ﬁbrillation (AF), a major risk factor
for HF [6]. While it is well established that ﬁbrinogen [7], VWF-VIII [8]
and D-dimer [8] are associated with increased risk of coronary heartre and Population Health, UCL,
amethee).
land Ltd. This is an open access articldisease (CHD), there is a lack of prospective studies of coagulation
markers and risk of incident HF.
In the British Regional Heart Study (BRHS), we have assayed a range
of coagulationmarkers inmen aged 60–79 years, and have previously re-
ported associations of ﬁbrinogen, VWF, Factors VIII and IX, and D-dimer
with incident myocardial infarction (MI) and CHD death [9]. No signiﬁ-
cant associations in this report were observed for Factors VII, activated
partial thromboplastin time (aPTT) or activated protein C (APC) resis-
tance, as measured by a low APC ratio [10]. To assess the possible role
of coagulation activation in pathogenesis of HF, we have now examined
the associations of these coagulation markers with incident HF, in those
menwho had no baseline diagnosis of HF or arterial or venous thrombo-
sis or who were taking warfarin. We also examined their associations
with baseline levels of NT-proBNP, and with the presence of atrial ﬁbril-
lation at baseline, to investigate associations with cardiac stress.
2. Subjects and methods
The British Regional Heart Study is a prospective study of cardiovascular disease
involving 7735 men aged 40–59 years drawn from general practice in each of 24 Britishe under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Baseline characteristics (1998–2000) in 3336 men without prevalent diagnosed myocar-
dial infarction, venous thrombosis or Heart Failure and whowere not on warfarin accord-
ing to incident Heart Failure status.
No HF (N = 3163) Developed HF (N = 203)
Age (yrs) 68.28 (5.45) 70.64 (5.45)
BMI (kg/m2) 26.73 (3.58) 27.53 (3.37)
% inactive 33.5 37.0
% current smokers 12.9 12.3
% manual 53.2 56.7
% heavy drinkers 3.7 6.4
% on antihypertensive drugs 27.0 42.4
% stroke 4.1 4.4
% diabetes 5.7 5.9
% renal dysfunction 13.6 22.2
% atrial ﬁbrillation 1.9 7.4
% LVH 7.2 14.3
SBP (mm Hg) 149.9 (23.8) 156.0 (23.0)
Cholesterol (mmol/L) 6.05 (1.05) 5.91 (1.04)
HDL-cholesterol (mmol/L) 1.33 (0.34) 1.33 (0.36)
CRP (mg/L)* 1.63 (0.79–3.23) 2.14 (1.03–3.68)
NT-proBNP (ng/L) 80.6 (41–152) 190.6 (81.5–405.5)
Fibrinogen (g/L) 3.24 (0.72) 3.38 (0.77)
D-dimer (μg/L)* 77.6 (48–122) 90.9 (51–127)
vWF (IU/L) 1369 (451) 1426 (482)
FVII (IU/L) 1199 (226) 1188 (268)
FVIII (IU/L) 1310 (314) 1353 (309)
FIX (IU/L) 1332 (226) 1347 (231)
APPT (s) 30.78 (3.42) 30.75 (2.54)
APC ratio 3.26 (0.50) 3.27 (0.52)
Mean (SD) unless speciﬁed; *geometric mean and interquartile range.
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socio-economically representative of British men but consisted almost entirely of white
Europeans (N99%). In 1998–2000, all surviving men, now aged 60–79 years (mean age
68.7 years), were invited for a 20th year follow-up examination. The men completed a
questionnaire which included questions on their medical history and lifestyle behaviour.
Theywere requested to fast for aminimumof 6 h, duringwhich time theywere instructed
to drink only water and to attend for measurement at a pre-speciﬁed time between 0800
and 1800 h. All men were asked to provide a blood sample, collected using the Sarstedt
Monovette system. 4252 men (77% of survivors) attended for examination. 4088 men
had at least one haemostatic/inﬂammatory marker measured. We excluded men with
doctor diagnosed MI or a recall of a diagnosis of deep vein thrombosis or pulmonary
embolism and men on warfarin (n = 722). After these exclusions 3366 men were
available for analysis.
2.1. Cardiovascular risk factor measurements at 1998–2000
Anthropometric measurements including body weight, height and waist circumfer-
ence (WC) were carried. Details of measurement and classiﬁcation methods for smoking
status, physical activity, social class, alcohol intake, blood pressure and blood lipids in
this cohort have been described [12–13]. Predicted glomerular ﬁltration rate (eGFR)
(measure of renal function) was estimated from serum creatinine using the equation
eGFR = 186 x (creatinine)-1.154 x (age)-0.203 [14]. Renal dysfunction was deﬁned as
eGFR b60. N-terminal pro-brain natriuretic peptide (NT-proBNP) was determined using
the Elecsys 2010 electrochemiluminescence method (Roche Diagnostics, Burgess Hill, UK)
[15]. Electrocardiographic LVH was deﬁned according to relevant Minnesota codes (codes
3.1 or 3.3). Atrial ﬁbrillation (AF)was deﬁned according toMinnesota codes 8.3.1 and 8.3.3.
2.2. Haemostatic and inﬂammatory markers
At the 20-year examination, blood was anticoagulatedwith 0.109M trisodium citrate
(9:1 v:v) for measurement of clottable ﬁbrinogen (Clauss method); as well as coagulation
factors VII, VIII and IX; activated partial thromboplastin time (APTT) and activated protein
C (APC) ratio (measured by the aPTT-based method) in an MDA-180 coagulometer
(Organon Teknika, Cambridge, UK). Plasma levels of D-dimer were measured
with enzyme-linked immunosorbent assays (Biopool AB, Umea, Sweden) as was von
Willebrand factor (VWF) antigen (DAKO, High Wycombe, UK). C-reactive protein
was assayed by ultra-sensitive nephelometry (Dade Behring, Milton Keynes, UK).
Distributions and laboratory coefﬁcients of variation have been described previously [9].
2.3. Follow-up
All men have been followed up from initial examination (1978–1980) for cardiovas-
cular morbidity [16] and follow-up has been achieved for 99% of the cohort. In the present
analyses, all-cause mortality and morbidity events are based on follow-up from
re-examination in 1998–2000 at mean age 60–79 years to June 2012. Survival times
ended at the ﬁrst heart failure event or when they were censored for death due to any
cause, or the end of the follow-up period (June 2012), whichever occurred ﬁrst.
Information on death was provided by the UK National Health Service registers. Fatal
CHD events were deﬁned as death with CHD (ICD 9th revision, codes 410–414) as the un-
derlying code. A non-fatal MI was diagnosed according to World Health Organisation
criteria. Evidence of non-fatal MI and HF was obtained by ad hoc reports from general
practitioners supplemented by biennial reviews of the patients' practice records
(including hospital and clinic correspondence) through to the end of the study period.
Incident CHD included fatal CHD and non-fatal MI. Incident non-fatal HF was based on a
doctor-conﬁrmed diagnosis of HF from primary care medical records (including hospital
and clinical correspondence) [15]. All cases were veriﬁed by a review of available clinical
information from primary and secondary care records (symptoms, signs, investigations,
and treatment response) to ensure they are consistent with current recommendations
on HF diagnosis [17]. Incident fatal HF cases were those in which the diagnosis of HF
was mentioned as the underlying cause of death at death certiﬁcates (ICD 9th revision
code 428). Incident HF included both incident non-fatal HF and incident fatal HF.
2.4. Statistical methods
Analyses are based on the division of haemostatic markers into equal quartiles. Cox's
proportional hazards model was used to assess the multivariate-adjusted relative risk for
the highest quarter compared with the lowest quarter (reference group). In multivariate
analyses, smoking (never, long term ex-smokers (N15 years), recent ex-smokers
(b15 years) and current smokers), social class (manual vs non manual), physical activity
(4 groups, diabetes (yes/no), use of antihypertensive treatment (yes/no), renal dysfunc-
tion (yes/no), LVH (yes/no) and AF (yes/no) were ﬁtted as categorical variables. Systolic
blood pressure, HDL-C and CRP were ﬁtted as continuous variables. Tests for trends
were carried out ﬁtting the haemostatic markers in its original continuous form. All
analyses were performed with SAS version 9.3 (SAS, Cary, North Carolina).
3. Results
During the mean follow-up period of 13 years there were 203
incident heart failure events in the 3366 men with no prevalent HF,arterial or venous thrombosis and who were not on warfarin, a rate of
5.5/1000 person years. Table 1 shows baseline characteristics in the
study population by incident HF status. Table 2 shows the association
between the coagulation markers and prevalence of AF and mean
NT-proBNP. Elevated D-dimer and vWF were signiﬁcantly associated
with higher prevalence of AF, but this was attenuated after adjustment
for age (p= 0.10 for trend for both variables). However, both markers
were signiﬁcantly associated with NT-proBNP, even after adjustment
for established risk factors and inﬂammation (Table 2). In contrast
Factor VII was inversely associated with both AF and NT-proBNP even
after adjustment for HF risk factors in Table 2. The adjusted odds ratio
of having AF in those with elevated Factor VII (top quartile) compared
to those in the bottom quartile was 0.27 (0.13,0.56) (p b 0.0001). The in-
verse association between Factor VII and AF remained even after addi-
tional adjustment for NT-proBNP (p = 0.02). Factor IX showed a
signiﬁcant inverse associationwithNT-proBNP, but only after adjustment.
We also examined the association between levels of NT-proBNP
and coagulation markers D-dimer, vWF and Factor VII to see whether
there is a threshold effect of NT-proBNP (Table 3). D-dimer and vWF
increased progressively with increasing NT-proBNP even after
adjustment. By contrast Factor VII decreased progressively with
increasing NT-proBNP.
Table 4 shows the association between the 8 coagulation markers
and risk of incident HF. With the exception of ﬁbrinogen, no signiﬁcant
association was seen between coagulation markers and incident HF
in age-adjusted analysis; and the association with ﬁbrinogen was
abolished after adjustment for risk factors for HF. Factor VII was inverse-
ly associated with incident HF only after adjustment for HF risk factors
but this was largely associated with NT-proBNP.
4. Discussion
In this study of older British men with no prevalent HF or arterial or
venous thrombosis andwhowere not onwarfarin, coagulationmarkers
including ﬁbrinogen, D-dimer, vWF, factors VII, VIII, IX, APC ratio
and APPT were not associated with incident HF after adjustment for
age and established HF risk factors. However, D-dimer and vWF were
signiﬁcantly associated with NT-proBNP, a marker of neurohormonal
Table 2
Markers of coagulation and associations with prevalent AF and baseline mean NT-proBNP
(ng/L) in men without prevalent diagnosed myocardial infarction, venous thrombosis or
heart failure and who were not on warfarin.
Quartiles
1 2 3 4 p-Trend
D-dimer
% AF 1.2 1.7 1.9 4.0 0.0004
NT-proBNP 58.0 79.5 90.8 124.6 b0.0001
*Adjusted 73.7 83.1 83.9 98.5 b0.0001
Fibrinogen
% AF 1.4 2.2 2.1 3.2 0.10
NT-proBNP 70.1 80.8 84.0 109.8 b0.0001
Adjusted 86.5 85.6 80.6 86.5 b0.50
vWF
% AF 1.6 1.8 2.7 2.8 0.18
NT-proBNP 70.1 75.8 86.4 113.0 b0.0001
Adjusted 81.5 79.8 83.9 93.7 0.008
Factor VII
% AF 4.0 2.9 0.9 1.3 b0.0001
NT-proBNP 103.5 87.4 77.5 75.9 b0.0001
Adjusted 107.8 85.6 79.0 72.2 b0.0001
Factor VIII
% AF 1.5 1.4 3.1 3.1 0.02
NT-proBNP 71.1 78.9 89.6 100.8 b0.0001
Adjusted 83.1 82.3 87.4 85.6 0.60
FACTOR IX
% AF 2.4 1.9 1.4 3.1 0.10
NT-proBNP 91.0 83.0 81.4 85.0 0.12
Adjusted 96.5 89.1 79.0 75.2 b0.0001
APPT
% AF 2.2 1.6 2.7 2.4 0.52
NT-proBNP 83.4 80.3 83.9 92.7 0.03
Adjusted 84.8 82.3 81.5 90.0 0.20
APC ratio
% AF 2.1 1.4 2.1 3.3 0.07
NT-proBNP 76.7 82.3 87.4 95.1 0.002
Adjusted 79.8 82.3 84.8 90.0 0.09
⁎ Adjusted for age, smoking, BMI, use of antihypertensive treatment, physical activity,
systolic blood pressure, LVH, prevalent stroke, renal dysfunction, heavy drinking, CRP
and AF.
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However, Factor VII was inversely associated with cardiac stress (AF
and NT-proBNP) even after adjustment. This is the ﬁrst comprehensive
prospective study of coagulation markers and incident HF.Table 3
Associations between levels of NT-proBNP and D-dimer and vWF in men without prevalen
not on warfarin.
N
b50 50–99 1
N = 966 N = 886 N
D-dimer (μg/L)
Adjusted mean 74.4 79.0 8
Adjusted odds elevated D-dimer 1.00 1.18 (0.92,1.51) 1
vWF (IU/L)
Adjusted mean 1327 1360 1
Adjusted odds elevated vWF 1.00 1.25 (0.98,1.58) 1
Factor VII (IU/L)
Adjusted mean 1237 1203 1
Adjusted odds elevated Factor VII 1.00 0.82 (0.66,1.01) 0
*Adjusted for age, smoking, BMI, use of antihypertensive treatment, physical activity, systolic b
Elevated =top tertile.4.1. Coagulation activation and incident heart failure
AlthoughD-dimer has been strongly associatedwith CHD and stroke
in this study [9,18,19], no association was seen between D-dimer and
incident HF. Similarly levels of vWF and Factor VIII related to incident
CHD, but not to HF. Fibrinogen was associated with HF in age-adjusted
analyses. This association was abolished after adjustment for other
established risk factors for HF. Although clinical studies have shown
activated protein C to have anti-inﬂammatory and anti-apoptotic effects
[20] and animal models have shown treatment with APC to protect
the development of myocardial ﬁbrosis which contributes to the
development of HF [21] no association was seen between APC resis-
tance (APC ratio) and risk of incident HF. Factor VII related inversely
to incident HF, which was only signiﬁcant in the multivariate analysis;
no signiﬁcant association was seen in the age-adjusted analyses. The
lack of association between all 8 coagulation markers studied and risk
of incident HF suggests that coagulation does not play a role in the
development of HF at least in older adults. This suggests that, in contrast
to coronary heart disease events which may have thromboembolic
mechanisms, heart failure in older adults is more related to other
pathophysiological mechanisms. This is in keeping with the ﬁndings
that older patients with HF tend to have preserved ejection fraction
[22]. In addition, these patients are less likely to have CHD and more
likely to have hypertension and atrial ﬁbrillation [23]. This is consistent
with the ﬁndings of our own study, in which a high proportion of men
without prior MI whowent on to develop HF did not develop MI before
developing HF (85%).4.2. Coagulation activation and baseline cardiac stress (NT-proBNP)
Chronic heart failure is increasingly recognised as a syndromewhich
confers a considerable prothrombotic risk [24,25]. The pathogenesis of
increased coagulation activation in such patients is complex and not
fully understood. Neurohormonal activation has been hypothesised to
be a prothrombotic mechanisms in patients with HF [24,25]. In HF
increasedwall stretch, neurohormonal activation and hypoxia stimulate
BNP secretion [26]. In this general population study, we have shown a
signiﬁcant association between NT-proBNP and D-dimer and vWF
independent of other known factors associated with NT-proBNP,
including inﬂammation, in subjects free of HF. Levels of D-dimer
and vWF increased progressively with increasing levels of NT-proBNP.
The ﬁndings of an association between coagulation activation with
NT-proBNP but not incident HF suggests that raised D-dimer and vWF
in those with HF is likely to be a consequence of neurohormonal
activation. By contrast we did not observe an association betweent diagnosed myocardial infarction, venous thrombosis or Heart Failure and who were
T-proBNP (ng/L)
00–149 150–299 300
= 437 N = 495 N = 354
3.1 90.0 93.7 b0.0001
.47 (1.10,1.98) 1.64 (1.23,2.17) 1.78 (1.27,2.49) b0.0001
377 1400 1435 b0.0001
.28 (0.96,1.71) 1.51 (1.14,2.00) 1.65 (1.19,2.29) 0.0008
213 1165 1129 b0.0001
.90 (0.69,1.17) 0.59 (0.45,0.78) 0.38 (0.27,0.54) b0.0001
lood pressure, LVH, prevalent stroke, renal dysfunction, heavy drinking, AF and CRP.
Table 4
Markers of coagulation and risk of HF in men with no prevalent MI, HF or DVT/PE and who are not on warfarin.
Quartiles
1 2 3 4 p-trend
D-Dimer
Rates/1000 p-yrs 4.4 5.7 5.5 6.7
Age-adjusted 1.00 1.06 (0.71,1.59) 0.91 (0.60,1.37) 1.02 (0.67,1.54) 0.18
Model 1 1.00 0.94 (0.62,1.41) 0.76 (0.49,1.17) 0.80 (0.52,1.25) 0.69
Fibrinogen
Rates/1000 p-yrs 3.3 5.7 6.0 6.8
Age-adjusted 1.00 0.95 (0.62,1.45) 1.26 (0.85,1.87) 1.37 (0.92,2.03) 0.01
Model 1 1.00 0.87 (0.56,1.34) 1.13 (0.74,1.72) 1.05 (0.65,1.68) 0.35
vWF
Rates/1000 p-yrs 4.2 5.6 6.0 6.5
Age-adjusted 1.00 1.23 (0.82,1.84) 1.24 (0.82,1.86) 1.22 (0.81,1.83) 0.23
Model 1 1.00 1.20 (0.79,1.82) 1.13 (0.74,1.72) 1.06 (0.69,1.62) 0.79
Factor VII
Rates/1000 p-yrs 5.9 6.5 5.2 4.6
Age adjusted 1.00 1.01 (0.70,1.47) 0.85 (0.57,1.25) 0.75 (0.50,1.12) 0.47
Model 1 1.00 0.97 (0.66,1.42) 0.79 (0.53,1.17) 0.64 (0.42,0.96) 0.07
Model 1 + NT-proBNP 1.00 1.04 (0.70,1.54) 0.90 (0.60,1.36) 0.80 (0.52,1.21) 0.63
Factor VIII
Rates/1000 p-yrs 3.8 5.6 6.0 6.8
Age adjusted 1.00 1.41 (0.93,2.14) 1.44 (0.94,2.20) 1.46 (0.96,2.22) 0.11
Model 1 1.00 1.42 (0.93,2.16) 1.29 (0.83,1.99) 1.28(0.82,1.98) 0.53
Factor IX
Rates/1000 p-yrs 4.3 5.4 6.9 5.6
Age-adjusted 1.00 1.24 (0.82,1.88) 1.52 (1.02,2.27) 1.28 (0.84,1.94) 0.17
Model 1 1.00 1.18 (0.77,1.80) 1.33 (0.88,2.01) 0.93 (0.59,1.46) 0.73
APPT
Rates/1000 p-yrs 5.6 5.2 5.5 5.8
Age-adjusted 1.00 0.93 (0.63,1.38) 1.00 (0.69,1.46) 1.05 (0.71,1.55) 0.85
Model 1 1.00 1.00 (0.67,1.49) 1.02 (0.69,1.49) 1.03 (0.69,1.54) 0.88
APC ratio
Rates/1000 p-yrs 4.8 5.5 5.8 6.1
Age-adjusted 1.00 1.07 (0.72,1.58) 1.10 (0.74,1.63) 1.20 (0.81,1.71) 0.76
Model 1 1.00 1.09 (0.73,1.62) 1.05 (0.70,1.59) 1.06 (0.71,1.64) 0.73
Model 1 adjusted for age, smoking, BMI, use of antihypertensive treatment, physical activity, systolic blood pressure, LVH, prevalent stroke, renal dysfunction, heavy drinking, CRP.
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exception of Factor VII no other coagulation markers related to AF.
4.3. Factor VII and cardiac stress and incident HF
An unexpected ﬁnding in the study was the inverse association seen
between Factor VII and NT-proBNP and AF and incident HF after
adjustment for established HF risk factors. The inverse association
between Factor VII and incident HF was however largely due to the
inverse association with NT-proBNP. The inverse association seen
between Factor VII and NT-proBNP may explain why low plasma con-
centrations of coagulation factor VII has been linked with increased of
CVDmortality in elderly patients with symptoms of HF [27]. The nature
of the inverse association between Factor VII and cardiac stress is
unclear and warrants further investigation in other studies.
4.4. Atrial ﬁbrillation in heart failure patients
Heart failure is common in patients with AF; these patients have
been shown to have signiﬁcantly higher 1-yearmortality andmorbidity
rates (resulting from a combination of stroke,thrombo-embolism and
transient ischaemic attacks) than AF patients without heart failure,
despite high rates of oral anticoagulant use [28]. We did not ﬁnd AF to
be associated with coagulation markers except inversely with factor
VII. In contrast, NT-proBNP (which is raised in heart failure) was signif-
icantly associated with vWF and D-dimer, factors shown to be associat-
ed with increased risk of stroke [19] and overall mortality. Thus,neurohormonal activation in heart failure may contribute to the
increased risk of stroke seen in AF patients with heart failure.
4.4.1. Strengths and limitations
We have included a comprehensive evaluation of coagulation
markers which have been related to other CVD outcomes including
CHD and stroke [9,19]. However, the ﬁndings are based on an older
predominantly white male population of European extraction, so that
the results cannot be generalized directly to women, younger popula-
tions or other ethnic groups. The current ﬁndings are based on doctor
diagnosed HF, which is likely to underestimate the true incidence of
HF in this study population. It is also possible that there is survival
bias in our data in that men who attended the re-examination were
healthier than those who did not; this may account for the null associa-
tions seen with prevalent AF. Although survivor bias may have affected
the absolute incidence rate of HF, this should not have affected the
associations between coagulation markers and incident HF. The
determinants of HF in this study population (including obesity and
NT-proBNP) [12,15] generally accord with prior data and therefore sug-
gest potential external validity for our ﬁndings. We had no information
on incident AF. Information on echocardiogrammeasurements was not
available in all men and we were not therefore able to differentiate
systolic and diastolic HF.
4.5. Conclusion
Wehave shown in a large prospective study of older Britishmen that
the coagulation markers D-dimer and vWF are associated with baseline
571S.G. Wannamethee et al. / International Journal of Cardiology 230 (2017) 567–571evidence of cardiac stress (NT-proBNP) but not with incident HF. We
conclude that coagulation activation in men at risk of HF may be a
consequence of neurohormonal activation and is not of causal signiﬁ-
cance in the development of HF. If so, future approaches for reducing
the thrombotic state in persons with CHF include pharmacological
modulation of neurohormonal activation. The unexpected ﬁnding of
an inverse association between Factor VII and cardiac stress requires
further investigation.
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